R&D channel feed

#AS­CO21: SQZ of­fers first clin­i­cal glimpse of un­ortho­dox cell ther­a­py man­u­fac­tur­ing tech — but check­point com­bo is still the way to go

5 years ago
Cell/Gene Tx

#AS­CO21: Co­herus, Jun­shi hunt US ap­proval for an­ti-PD-1 drug in nose and throat can­cer with late-stage win

5 years ago

#AS­CO21: Nanobi­otix says ear­ly da­ta show 'very strong' sig­nal that its nanopar­ti­cles can di­al up an­ti­tu­mor re­sponse

5 years ago

#AS­CO21: Bris­tol My­er­s' so­lo, dual I/O reg­i­mens best chemo alone — with one ex­cep­tion — in first-line esophageal pa­tients

5 years ago

#AS­CO21: As­traZeneca's Lyn­parza earns win in ear­ly breast can­cer pa­tients, crack­ing open post-surgery po­ten­tial

5 years ago
Pharma

#AS­CO21: Mer­ck keeps chop­ping away at a path to ear­ly can­cer pa­tients for Keytru­da, this time in kid­ney

5 years ago

Just months af­ter SPAC re­verse merg­er, Point Bio­phar­ma ups the ante at In­di­anapo­lis man­u­fac­tur­ing site

5 years ago
Manufacturing

Aa­van­tiBio lands man­u­fac­tur­ing part­ner in Friedre­ich's Atax­ia pro­gram; NC Re­search Tri­an­gle lands an­oth­er CD­MO

5 years ago
Manufacturing

A Bel­gian man­u­fac­tur­er looks to pit its freeze dry­ing process against mR­NA — and be­yond

5 years ago
Manufacturing

Covid-19 man­u­fac­tur­ing roundup: Af­ter Emer­gent dis­as­ter, As­traZeneca in talks to move to Catal­ent plant — re­port; Sinopharm says it has ca­pac­i­ty to pro­duce 5B vac­cines

5 years ago
Manufacturing

#AS­CO21: No­var­tis flash­es 'ground­break­ing data' for $2B ra­di­oli­gand drug

5 years ago

#AS­CO21: No­var­tis gears up for CAR-T fight with Gilead in fol­lic­u­lar lym­phoma — and safe­ty could de­fine the bat­tle

5 years ago

#AS­CO21: No­var­tis keeps build­ing out sur­vival da­ta for Kisqali, hop­ing to add pres­sure on Pfiz­er's Ibrance

5 years ago
Pharma

Ex­clu­sive: Carl June’s Tmu­ni­ty en­coun­ters a lethal road­block as 2 pa­tient deaths de­rail lead tri­al, raise red flag forc­ing a re­think of CAR-T for sol­id tu­mors

5 years ago

Af­ter tak­ing a look at new da­ta, reg­u­la­tors put J&J's BC­MA/CD3 bis­pe­cif­ic on a 'break­through' track

5 years ago
FDA+

No­var­tis stakes an­oth­er PhI­II win for Cosen­tyx, goes deep­er in­to pe­di­atric mar­kets

5 years ago

A sim­ple pa­tient sur­vey rev­o­lu­tion­ized ALS drug de­vel­op­ment in the 1990s. Its cre­ator says it may be time for an up­grade

5 years ago
In Focus

Im­muno­vant flash­es se­cret da­ta be­hind po­ten­tial Roivant buy­out, but in­vestors see a dif­fi­cult fu­ture

5 years ago

Months af­ter ax­ing a Duchenne pro­gram and lay­ing off dozens, San­thera claims a win there with a dif­fer­ent pro­gram

5 years ago

Clin­i­cal stud­ies for AB Sci­ence's all-pur­pose an­ti-in­flam­ma­to­ry drug grind to a halt as com­pa­ny flags po­ten­tial risk of heart dis­ease

5 years ago

No­var­tis scraps a slate of Beovu tri­als af­ter 4-week dos­ing turned up safe­ty is­sues — dash­ing hopes of de­thron­ing Eylea

5 years ago
Pharma

Sanofi slash­es an­oth­er pro­gram for key mol­e­cule, while keep­ing hopes in hand­ful of rare dis­eases

5 years ago
Pharma

FDA hands a CRL to drug­mak­er Eton af­ter a de­layed in­spec­tion — but are Covid-19 trav­el re­stric­tions re­al­ly the is­sue?

5 years ago
FDA+

No price com­pe­ti­tion in PD-(L)1? That might not last long as EQRx, CStone read out late-stage win for chal­lenger

5 years ago
First page Previous page 168169170171172173174 Next page Last page
A service from the Financial Times